Beyond Barriers Therapeutics
3 known investors
Beyond Barriers Therapeutics develops BBT-101, an intranasal therapy for mild and moderate concussions intended for rapid deployment at the point of injury. The company focuses on providing the first FDA-approved frontline treatment for brain injuries across military, athletic, and civilian populations.
Also known as BBT · Beyond Barriers Therapeutics, Inc.
Investors · 3
Company profile
researched Aug 2026Beyond Barriers Therapeutics (BBT) is a clinical-stage biotechnology company developing BBT-101, an intranasal therapeutic intended to mitigate the secondary damaging effects of mild traumatic brain injury (mTBI, or concussion) and moderate TBI. The product is positioned as a frontline, field-deployable intervention to be administered in the moments immediately after impact, addressing what the company describes as the absence of an FDA-approved treatment at the point of injury. The company cites an estimated 3 million concussions annually in the United States and 69 million globally, with roughly one in two going undiagnosed.
BBT-101 is a first-in-class intranasal formulation of N-acetylcysteine (NAC), an antioxidant intended to raise brain glutathione and reduce neuroinflammation, swelling and oxidative stress. The company's patented nose-to-brain delivery system is designed to bypass first-pass metabolism, and the company states the optimized formulation should deliver roughly 10x greater bioavailability and act about 4x faster than orally delivered NAC while reducing side effects associated with oral administration. Development is being pursued through the FDA's 505(b)(2) pathway, leveraging NAC's 50-plus-year safety record, more than 20 preclinical animal studies in TBI, and two human clinical trials in mild TBI. Beyond acute TBI, the company describes potential future indications including pediatric concussion, seizures, stroke, blast injury, and neurodegenerative conditions such as Alzheimer's and Parkinson's disease.
The company reports a research collaboration with the University of Miami involving Dr. Michael Hoffer, a neurosurgeon and co-principal investigator overseeing one of its clinical trials, and states it has support from the U.S. Department of Defense, the NFL Players Association (NFLPA), and U.S. Special Operations Command. Its leadership team and advisory board are described as spanning military and trauma medicine, FDA regulatory affairs, nasal drug delivery, CNS therapeutic development, and medical device innovation. A third-party life sciences database lists BBT-101 at preclinical stage with brain concussion as the active indication.
Founding story
The company began as a project of University of Chicago and Northwestern graduate students, who in 2015 won the National Institutes of Health (NIH) Neuro Startup Challenge. It subsequently developed into Beyond Barriers Therapeutics, a clinical-stage biotechnology company focused on intranasal treatment of traumatic brain injury.
Traction
The company describes itself as clinical-stage, with a University of Miami research collaboration under co-principal investigator Dr. Michael Hoffer overseeing one of its clinical trials, and cites support from the U.S. Department of Defense, the NFLPA and U.S. Special Operations Command. Two issued U.S. patents protect BBT-101, with further filings pending. An external pipeline database lists BBT-101 at preclinical stage for brain concussion. An investor directory lists one disclosed backer, Partners Resolute, at seed stage.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
The company positions BBT-101 as the first frontline, point-of-injury therapy for mild and moderate concussion, noting that no FDA-approved treatment exists at the point of injury and that the FDA has approved NAC only for potentially hepatotoxic doses of acetaminophen. A third-party investor directory categorizes the company in biotech and life sciences at seed stage.
Differentiation is attributed to the patented intranasal, nose-to-brain delivery route that bypasses first-pass metabolism for faster, more targeted effect, combined with reuse of an active ingredient with a 50-plus-year safety record via the 505(b)(2) regulatory pathway, and a field-deployable format intended for administration within moments of injury.
Technology
BBT-101 is an intranasal formulation of the repurposed active ingredient N-acetylcysteine (NAC), an antioxidant described as increasing brain glutathione and reducing neuroinflammation, swelling and oxidative stress. The patented nose-to-brain delivery system bypasses first-pass metabolism, which the company says should yield approximately 10x greater bioavailability and 4x faster action than oral NAC, along with reduced side effects. Development uses the FDA 505(b)(2) pathway, building on NAC's long safety record, more than 20 preclinical animal TBI studies, and two human clinical trials in mild TBI. U.S. Patent Nos. 11,612,642 and 12,257,292 cover BBT-101 and its use in CNS disorders including TBI, Parkinson's disease, Huntington's disease, stroke, depression, bipolar disorder, Alzheimer's disease and ALS, with additional applications pending in the U.S. and other jurisdictions.
Go-to-market
The company states it is actively seeking partners in science, medicine and investment, and works through research collaborations (University of Miami) and support from defense and sports organizations including the U.S. Department of Defense, U.S. Special Operations Command and the NFLPA.
Stated beneficiary groups include first responders, active-duty service members and veterans; athletes, particularly youth and female athletes, and their teams; patients facing neurodegeneration (Alzheimer's, chemo brain, Parkinson's disease, stroke recovery); and neurotrauma clinicians, caregivers and advocates in field, frontline and emergency-room settings.
Geography
United States-based; a third-party database lists the company as registered in Illinois, with research collaboration activity through the University of Miami in Florida.
History
Originating from a graduate-student project at the University of Chicago and Northwestern that won the NIH Neuro Startup Challenge in 2015, the company has since advanced BBT-101 as an intranasal therapeutic for mild and moderate TBI, obtaining two U.S. patents (11,612,642 and 12,257,292) and establishing a clinical research collaboration with the University of Miami.
Risks & controversies
The company's own legal notice states that the FDA has approved N-acetylcysteine only for potentially hepatotoxic doses of acetaminophen, that intravenous NAC formulations have been reported to carry risks of serious anaphylactoid reaction and acute flushing and erythema of the skin, that hypersensitivity reactions including generalized urticaria have been observed with oral NAC in acetaminophen overdose, and that the risks of administering NAC intranasally are currently unknown. BBT-101 is not approved, and a third-party pipeline database lists it at preclinical stage.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 4
launches, deals, and filingsBBT reports a research collaboration with the University of Miami involving Dr. Michael Hoffer, a neurosurgeon and co-principal investigator overseeing one of the company's clinical trials.
A second U.S. patent, No. 12,257,292, protects BBT-101 and its use in treating CNS disorders; additional patent rights are pending in the U.S. and other jurisdictions.
U.S. Patent No. 11,612,642 protects BBT-101 and its use in the treatment of CNS disorders including TBI, Parkinson's disease, Huntington's disease, stroke, depression, bipolar disorder, Alzheimer's disease and ALS.
The company originated as a project of University of Chicago and Northwestern graduate students who won the National Institutes of Health Neuro Startup Challenge in 2015.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- Beyond Barriers Therapeuticsbeyondbarrierstherapeutics.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Beyond Barriers Therapeutics do?
- Clinical-stage biotech developing BBT-101, an intranasal N-acetylcysteine therapy for mild and moderate traumatic brain injury.
- Who are Beyond Barriers Therapeutics's investors?
- Beyond Barriers Therapeutics's investors include Chicago Early Growth Ventures (CEGV), Illinois Ventures, Partners Resolute.